Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.735 -0.275 (-6.86%)
Streaming Delayed Price Updated: 2:07 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
All The Stocks That Moved Wednesday From CNBC's 'Fast Money: Halftime Report' ↗
CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often move the stocks mentioned.... 
Via Benzinga
News headline image
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Recap: Iovance Biotherapeutics Q4 Earnings ↗
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
News headline image
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers SOC Telemed (NASDAQ:TLMD) stock increased by 30.04% to $2.77 during Friday's regular session. The current volume of 1.9 million shares is 238.17% of SOC... 
Via Benzinga
News headline image
48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares climbed 41% to $9.28 after the company reported better-than-expected Q3results and issued Q4 sales guidance above... 
Via Benzinga
News headline image
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript ↗
IOVA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
Why Iovance Is Up Nearly 11% Today ↗
Investors are starting to connect some drug development dots... with a little help. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll ↗
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed... 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Soared 40% In June ↗
The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon. 
Via The Motley Fool
News headline image
June’s Best and Worst Performing Russell 1,000 Stocks ↗
The month of June, the second quarter and the first half of 2021 are almost in the bag. 
Via Talk Markets
News headline image
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2.... 
Via Benzinga
News headline image
Should You Buy This Cathie Wood Biotech Stock? ↗
This biotech's fumble has caught the attention of a fund manager known for making innovative investments. 
Via The Motley Fool
News headline image
Best and Worst Russell 1000 Stocks So Far in June ↗
Right at the midpoint of June, Biogen has been the top-performing Russell 1,000 stock month to date. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 16.17% to $3.16 during Thursday's regular session. NuCana's stock is trading at a volume of 4.7 million shares... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
News headline image
Iovance's Lifileucel Shows Meaningful Increase in Response Time with Primary Anti-PD-1 Resistance in Melanoma Trial ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced updated clinical data for lifileucel from Cohort 2 of C-144-01 clinical study in patients with advanced melanoma. Data... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
News headline image
Most of ARKK Bouncing But Still Down Big ↗
After trading deep into oversold territory, the past two weeks have seen the ARK Innovation ETF erase some of the losses of the past few months. 
Via Talk Markets
News headline image
10 Biggest Price Target Changes For Monday ↗
Morgan Stanley raised Deere & Company (NYSE: DE) price target from $410 to $450. Deere shares rose 0.4% to $361.00 in pre-market trading. Oppenheimer cut Iovance... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.